Botox Nabota 200 Units

Kuvaus

Nabota 200 Units (prabotulinumtoxinA-xvfs) is a purified botulinum toxin type A complex produced by Daewoong Pharmaceutical and distributed globally (marketed as Jeuveau in the United States by Evolus). It contains 200 units of vacuum-dried neurotoxin powder in a single-use vial, reconstituted with preservative-free 0.9% sodium chloride solution before injection. Nabota works by inhibiting acetylcholine release at the neuromuscular junction, producing precise, temporary muscle paralysis or reduced glandular activity—widely regarded as a high-quality, cost-effective alternative to other botulinum toxins with comparable efficacy and duration.

Aesthetic Uses

Nabota 200 Units is approved in many countries (and as Jeuveau in the US) for the temporary improvement of moderate to severe:

• Glabellar frown lines
• Lateral canthal lines (crow’s feet)
• Horizontal forehead lines

The 200-unit vial is particularly advantageous for:

• Full-face or multi-area treatments in one session
• Busy aesthetic clinics serving multiple patients
• Patients requiring higher total doses (stronger facial muscles, men, or combination protocols)
• Off-label uses such as masseter reduction (jaw slimming), platysmal bands, bunny lines, perioral rhytids, gummy smile, or hyperhidrosis

Typical cosmetic doses range from 20–80 units per session (depending on areas treated), with onset in 3–7 days, peak effect at 10–14 days, and duration of 3–6 months (often comparable to Botox in head-to-head studies).

Therapeutic Uses

Nabota is approved or used off-label in various regions for:

• Cervical dystonia
• Blepharospasm and hemifacial spasm
• Upper/lower limb spasticity
• Chronic migraine
• Sialorrhea (excessive drooling)
• Focal hyperhidrosis

Therapeutic doses vary significantly (e.g., 100–300+ units total), requiring expert placement and often EMG guidance.

Administration & Handling

• Reconstitute with 2.0–4.0 mL sterile, preservative-free saline (yielding 5–10 U/0.1 mL depending on dilution)
• Use within 24 hours when refrigerated (2–8°C)
• Inject with fine-gauge needles (30–33G) or cannulas in aesthetic work

Safety & Side Effects

Common side effects are mild and transient: injection-site pain, swelling, bruising, headache, eyelid ptosis, dry eyes, or mild flu-like symptoms. Serious but rare risks include distant spread of toxin effects (dysphagia, respiratory issues), allergic reactions, or antibody-mediated resistance (comparable or lower than other toxins in studies). Contraindications include hypersensitivity to botulinum toxin or human albumin, active infection at injection site, and certain neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS).

As of 2026, Nabota 200 Units is approved in over 60 countries (including the US as Jeuveau, Europe, Asia, Latin America, and the Middle East) and has gained strong market share due to its high purity, competitive pricing, and consistent performance. The 200-unit vial provides excellent flexibility and cost-efficiency for clinics and practitioners. Nabota must be administered only by qualified healthcare professionals (dermatologists, plastic surgeons, neurologists, etc.) trained in botulinum toxin injection techniques, with proper patient assessment, informed consent, and follow-up. Always use genuine Nabota from authorized distributors to ensure safety, potency, and authenticity.